A Form 4 filed on September 4, 2026, discloses that J. Anthony Ware, a director of First Tracks Biotherapeutics, Inc., exercised stock options and sold common shares on September 2, 2026.

Key Highlights

  • Option exercise: Ware exercised two fully vested stock options on September 2, 2026, acquiring a combined 39,265 shares of common stock at an exercise price of $5.74 per share.
  • Shares sold: 39,265 shares of common stock were sold on September 2, 2026, at a weighted average price of $44.7764 per share, with individual sale prices ranging from $44.62 to $45.28 per share.
  • Remaining direct ownership: Following the transactions, Ware directly beneficially owned 15,660 shares of common stock.
  • Additional holdings: According to the filing, Ware also holds options to purchase up to an aggregate of 99,320 shares of common stock and 6,500 restricted stock units, separate from the shares reported in Table I.
  • Expired derivative positions: Both exercised stock options, originally covering 28,571 shares and 10,694 shares respectively, were extinguished, leaving zero derivative securities beneficially owned in those positions.

Director Ware's Option Exercise and Sale at First Tracks Biotherapeutics

According to the filing, J. Anthony Ware, identified as a director of First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX), executed two related transactions on September 2, 2026. First, Ware exercised two fully vested stock options under transaction code "M," acquiring a total of 39,265 shares of common stock. The two options covered 28,571 shares and 10,694 shares respectively, each with a conversion or exercise price of $5.74 and an expiration date of August 21, 2027. The filing reports the price of each derivative security upon exercise as $0.

On the same date, the filing reports that Ware disposed of 39,265 shares of common stock under transaction code "S" at a weighted average sale price of $44.7764 per share. The filing notes that the shares were sold in multiple transactions at prices ranging from $44.62 to $45.28 per share. The filing states that Ware "undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."

Prior to the reported transactions, the filing indicates Ware beneficially owned 54,925 shares directly. After the exercise and subsequent sale, direct beneficial ownership stood at 15,660 shares. The Form 4 was signed by Ajim Tamboli as attorney-in-fact on September 4, 2026.

What Was Disclosed

The filing discloses a same-day option exercise and share sale by director J. Anthony Ware on September 2, 2026, resulting in direct beneficial ownership of 15,660 shares of First Tracks Biotherapeutics common stock, plus separately held options on 99,320 shares and 6,500 restricted stock units.